-
公开(公告)号：US20150259748A1
公开(公告)日：2015-09-17
申请号：US14726343
申请日：2015-05-29
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
CPC分类号： C12Q1/6883 , C12Q2600/156 , G01N33/6893 , G01N2800/065 , G01N2800/50
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
摘要翻译： 本发明提供诊断，预测和诊断易感性，预测疾病进展和治疗炎症性肠病（IBD）的方法，包括克罗恩病和/或克罗恩病（CD）和/或溃疡性结肠炎（UC）的亚型。 在一个实施方案中，本发明的方法通过确定遗传变体NOD2，TLR8，TLR2，CARD8，CARD15和/或JAK3的存在或不存在来诊断，预测和诊断易感性并预测个体的疾病进展。 在另一个实施方案中，通过确定个体中抗Cbir1，抗OmpC，ASCA，抗-12和/或pANCA的存在或不存在来实施本发明的方法。 在另一个实施方案中，本发明进一步将风险变异体的存在或不存在与抗Cbir1，抗OmpC，ASCA，抗-I 2和/或pANCA的表达有关用于诊断，预测易感性，预测疾病进展和 /或治疗IBD，包括CD和/或UC。
-
公开(公告)号：US20200149110A1
公开(公告)日：2020-05-14
申请号：US16683141
申请日：2019-11-13
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
IPC分类号： C12Q1/6883 , G01N33/68
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
-
公开(公告)号：US12110555B2
公开(公告)日：2024-10-08
申请号：US17588089
申请日：2022-01-28
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
IPC分类号： C12Q1/68 , C12Q1/6883 , G01N33/68
CPC分类号： C12Q1/6883 , G01N33/6893 , C12Q2600/156 , G01N2800/065 , G01N2800/50
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
-
公开(公告)号：US20220290235A1
公开(公告)日：2022-09-15
申请号：US17588089
申请日：2022-01-28
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
IPC分类号： C12Q1/6883 , G01N33/68
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
-
公开(公告)号：US20150337378A1
公开(公告)日：2015-11-26
申请号：US14722018
申请日：2015-05-26
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to methods of diagnosing and predicting susceptibility to Crohn's Disease and/or IBD, by determining the presence or absence of susceptibility to genetic variants, risk haplotypes and/or protective haplotypes. In an embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk variants at the IL12RB1, IL12RB2, IL17A, IL17RA, IL17RD and/or IL23R locus.
摘要翻译： 本发明涉及诊断和预测对克罗恩病和/或IBD敏感性的方法，通过确定对遗传变异体，风险单倍型和/或保护性单元型的易感性的存在或不存在。 在一个实施方案中，本发明提供了通过确定在IL12RB1，IL12RB2，IL17A，IL17RA，IL17RD和/或IL23R基因座处存在或不存在风险变体来诊断和/或预测个体中克罗恩病易感性的方法。
-
公开(公告)号：US11268149B2
公开(公告)日：2022-03-08
申请号：US16683141
申请日：2019-11-13
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
IPC分类号： C12P19/34 , C12Q1/6883 , G01N33/68
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
-
7.发明授权公开(公告)号：US10544459B2
公开(公告)日：2020-01-28
申请号：US14726343
申请日：2015-05-29
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
IPC分类号： C12P19/34 , C12Q1/6883 , G01N33/68
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
-
公开(公告)号：US20180208988A1
公开(公告)日：2018-07-26
申请号：US15921160
申请日：2018-03-14
IPC分类号： C12Q1/6883
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to methods of diagnosing and predicting susceptibility to Crohn's Diseaese and/or IBD, by determining the presence or absence of susceptibility to genetic variants, risk haplotypes and/or protective haplotypes. In an embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk variants at the IL12RB1, IL12RB2, IL17A, IL17RA, IL17RD and/or IL23R locus.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.021 秒)
